AIM ImmunoTech logo
AIM ImmunoTech AIM
$ 0.11 -8.33%
report update icon

Quarterly report 2026-Q3
added 11-12-2026

AIM ImmunoTech Net Income | AIM

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income AIM ImmunoTech

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
-14 M -17.3 M -29 M -19.4 M -19.1 M -14.4 M -9.53 M -9.81 M -8.26 M -7.5 M -15.2 M -17.4 M -16.2 M -17.4 M -9.02 M -2.5 M -7.18 M -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-2.5 M -29 M -13.7 M

Quarterly Net Income AIM ImmunoTech

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
-3.14 M -3.79 M -3.02 M -4.18 M -3.28 M -2.79 M -3.7 M -5.97 M -3.7 M -1.84 M -5.82 M -12.6 M -7.82 M -4.91 M -3.66 M - -6.38 M -4.85 M -3.82 M - -3.83 M -5.88 M -3.58 M - -3.31 M -3.37 M -3.81 M - -2.95 M -2.04 M -3.36 M - -3.08 M -2.42 M -2.71 M - -1.25 M -2.19 M -2.82 M - -2.86 M -1.3 M -2.16 M -3.14 M -3.8 M -4.84 M -3.44 M -4.46 M -4.2 M -4.96 M -3.84 M -3.2 M -5.14 M -4.28 M -3.61 M -5.46 M -6.59 M -3 M -2.31 M -3.12 M -2.74 M -2.29 M -866 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
-866 K -12.6 M -3.81 M

References

  1. Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer Net Income Price % 24h Market Cap Country
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-10.4 M - 3.16 % $ 1.9 M usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
-70.8 M - -15.15 % $ 60.3 M britainBritain
TFF Pharmaceuticals TFF Pharmaceuticals
TFFP
-21.2 M - -60.05 % $ 125 K usaUSA
Codiak BioSciences Codiak BioSciences
CDAK
-37.2 M - -55.98 % $ 2.15 M usaUSA
Sage Therapeutics Sage Therapeutics
SAGE
-401 M - - $ 527 M usaUSA
Paratek Pharmaceuticals Paratek Pharmaceuticals
PRTK
-63.6 M - - $ 121 M usaUSA
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
-7.26 M - - $ 521 M usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
-3.18 M $ 34.99 3.77 % $ 147 M usaUSA
Seelos Therapeutics Seelos Therapeutics
SEEL
-37.9 M - -47.76 % $ 6.27 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
37.2 M - - - russiaRussia
Kiromic BioPharma Kiromic BioPharma
KRBP
-26.9 M - 6.61 % $ 3.08 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
-195 M - - $ 2.18 B usaUSA
Fusion Pharmaceuticals Fusion Pharmaceuticals
FUSN
-94.9 M - - $ 1.41 B canadaCanada
Gritstone Oncology Gritstone Oncology
GRTS
-138 M - 0.42 % $ 213 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
-30.4 M - 17.91 % $ 11.1 M usaUSA
Titan Pharmaceuticals Titan Pharmaceuticals
TTNP
-4.71 M - -3.76 % $ 3.47 M usaUSA
HOOKIPA Pharma HOOKIPA Pharma
HOOK
-43.5 M - -6.92 % $ 79.4 M usaUSA
Otonomy Otonomy
OTIC
-51.2 M - -1.96 % $ 4.68 M usaUSA
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated
LGND
124 M $ 286.96 0.01 % $ 5.55 B usaUSA
Фармсинтез Фармсинтез
LIFE
-525 M - - - russiaRussia
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
-33.9 M $ 1.04 -4.59 % $ 32.4 M usaUSA
Oncternal Therapeutics Oncternal Therapeutics
ONCT
-39.5 M - -24.12 % $ 1.56 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-18.4 M - - $ 26.5 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
-80.1 M - - $ 401 M usaUSA
Histogen Histogen
HSTO
-10.6 M - 31.6 % $ 2.12 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
-56.2 M - - $ 169 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
-64.4 M - -7.23 % $ 13 M usaUSA
Taro Pharmaceutical Industries Ltd. Taro Pharmaceutical Industries Ltd.
TARO
25.4 M - - $ 1.62 B israelIsrael
Omeros Corporation Omeros Corporation
OMER
-3.35 M $ 13.23 -5.71 % $ 840 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
-2.03 M $ 0.94 -10.44 % $ 2.32 B israelIsrael
PhaseBio Pharmaceuticals PhaseBio Pharmaceuticals
PHAS
-131 M - 7.4 % $ 6.29 M usaUSA
Forma Therapeutics Holdings Forma Therapeutics Holdings
FMTX
-173 M - - $ 958 M usaUSA
Blueprint Medicines Corporation Blueprint Medicines Corporation
BPMC
-67.1 M - - $ 8.14 B usaUSA
Horizon Therapeutics Public Limited Company Horizon Therapeutics Public Limited Company
HZNP
521 M - - $ 26.6 B irlandaIrlanda
Provention Bio Provention Bio
PRVB
-114 M - - $ 2.37 B usaUSA
Reata Pharmaceuticals Reata Pharmaceuticals
RETA
-312 M - - $ 6.29 B usaUSA
PainReform Ltd. PainReform Ltd.
PRFX
-5.02 M $ 0.47 -24.53 % $ 305 K israelIsrael
iTeos Therapeutics iTeos Therapeutics
ITOS
-134 M - - $ 411 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
-9.83 M $ 1.44 -2.03 % $ 2.37 M israelIsrael
PolarityTE PolarityTE
PTE
-7.83 M - -0.82 % $ 1.78 M usaUSA
Kronos Bio Kronos Bio
KRON
-86.1 M - 1.49 % $ 50.8 M usaUSA
Cullinan Management Cullinan Management
CGEM
-220 M $ 8.9 -1.93 % $ 536 M usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
-582 M $ 39.15 0.57 % $ 3.52 B schweizSchweiz
Advaxis Advaxis
ADXS
-48.1 M - -9.65 % $ 45.9 M usaUSA
Stoke Therapeutics Stoke Therapeutics
STOK
-6.88 M $ 26.77 -0.59 % $ 1.59 B usaUSA
Trevena Trevena
TRVN
-40.3 M - -46.58 % $ 31.8 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
-39.6 M - -10.95 % $ 876 K usaUSA
Molecular Templates Molecular Templates
MTEM
-8.12 M - -23.43 % $ 495 K usaUSA
Oncorus Oncorus
ONCR
-77.4 M - -8.54 % $ 3.19 M usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
-69.9 M $ 0.07 9.81 % $ 855 K usaUSA